Acticor Biotech Appoints Dr Andrea Comenducci as Medical Director


Dec 18, 2018--Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombo-embolic diseases, including stroke and pulmonary embolism, today announced the appointment of Dr Andrea Comenducci MD as Medical Director in charge of clinical R&D and medical affairs. Dr Comenducci specialises in the cardiovascular field, and his priority will be to lead, with the support of a strengthened clinical team, the current Phase II clinical trial of ACT017, Acticor Biotech's flagship product for acute ischemic stroke.



from Biotech News